CBER outlines future biologics, biosimilars plans

With greater development of biologic medications, biosimilars and companion diagnostics, the FDA Center for Biologics Evaluation and Research's role in health care is growing, speakers said at FDLI's annual meeting. CBER office directors discussed plans for the center, which include a push to publish the draft guidance Preclinical Safety Assessment of Investigational Cellular and Gene Therapy Products.

View Full Article in:

CBER Importance Boosted With Attention To Biologic Drugs, Biosimilars, Speakers Say - Bloomberg BNA

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Program Coordinator/Lecturer for the Regulatory Science program
Johns Hopkins University
Washington, DC